pharma news today obesity drugs glp-1 october 2025 Giants Bet on Next-Generation Treatments to Sustain Growth GLP‑1 real‑world data for obesity:

Yet the identity of the downstream signalling events mediated by these peptides remain to be elucidated

We talk to Dr

If approved, it will certainly bea case of profoundly delayed gratification. Tough for me not see some level of sour grapes here indeed, the process of drug discovery is complex, long and riddled with failures we now have the amazing biotechnology advances of liraglutide, semaglutide, tirzetapide, and many more to come, that should be celebrated for the millions, to over a billion lives, that can be improved across the world

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve access, reduce side effects, and support sustainable weight loss.

But sooner or later, almost everyone on one asks the same question

What Is A GLP-1 Agonist